H.C. Wainwright raised the firm’s price target on SpringWorks Therapeutics to $73 from $64 and keeps a Buy rating on the shares. The analyst says safety concerns should result in only minor delays for Ogsiveo use in women of childbearing potential. The firm increased the number of U.S. desmoid tumors patients who are receiving therapy to 5,000 from the prior 3,500 patients after consulting with various key opinion leaders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- SpringWorks Therapeutics price target raised to $50 from $45 at BofA
- SpringWorks Therapeutics price target raised to $52 from $47 at Goldman Sachs
- SpringWorks Therapeutics price target raised to $64 from $52 at H.C. Wainwright
- SpringWorks Stock (NASDAQ:SWTX) Rallies on FDA’s Rare Tumor Drug Approval